Story thread · 2 reports / 2 sources
Royalty Pharma expects modest return despite pelacarsen trial failure
investing.com · 10d
First report: Teva posts mid-stage trial win for celiac disease therapy developed with Royalty Pharma — seekingalpha.com, 12d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.